Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron Post-Rezum for BPH Symptoms
NCT07017439Phase 3Not yet recruiting
- Sponsor
- University of Manitoba
- Start
- Aug 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) comparing Mirabegron Arm with Placebo Arm (2 arms). Primary endpoint: Change in symptom scores at 4 weeks. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
mirabegron
03
Conditions
benign prostatic hyperplasia (BPH)lower urinary tract symptoms (LUTS)
Beyond the preview
Go deeper on NCT07017439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07017439.